268 related articles for article (PubMed ID: 30528328)
1. Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge.
Lakhal-Naouar I; Koles N; Rao M; Morrison EB; Childs JM; Alving CR; Aronson NE
Vaccine; 2019 Jan; 37(3):516-523. PubMed ID: 30528328
[TBL] [Abstract][Full Text] [Related]
2. PEGylation of cationic liposomes encapsulating soluble Leishmania antigens reduces the adjuvant efficacy of liposomes in murine model.
Naseri H; Eskandari F; Jaafari MR; Khamesipour A; Abbasi A; Badiee A
Parasite Immunol; 2017 Nov; 39(11):. PubMed ID: 28921566
[TBL] [Abstract][Full Text] [Related]
3. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
[TBL] [Abstract][Full Text] [Related]
4. Induction of protection against leishmaniasis in susceptible BALB/c mice using simple DOTAP cationic nanoliposomes containing soluble Leishmania antigen (SLA).
Firouzmand H; Badiee A; Khamesipour A; Heravi Shargh V; Alavizadeh SH; Abbasi A; Jaafari MR
Acta Trop; 2013 Dec; 128(3):528-35. PubMed ID: 23916506
[TBL] [Abstract][Full Text] [Related]
5. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.
Heravi Shargh V; Jaafari MR; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Badiee A
Parasitol Res; 2012 Jul; 111(1):105-14. PubMed ID: 22223037
[TBL] [Abstract][Full Text] [Related]
6. Co-administration of chitin micro-particle and Leishmania antigen proposed a new immune adjuvant against experimental leishmaniasis.
Azizi M; Yousefi R; Yeganeh F; Mami S; Haji Molla Hoseini M
Parasite Immunol; 2019 Dec; 41(12):e12676. PubMed ID: 31593609
[TBL] [Abstract][Full Text] [Related]
7. The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63).
Badiee A; Jaafari MR; Khamesipour A; Samiei A; Soroush D; Kheiri MT; Barkhordari F; McMaster WR; Mahboudi F
Exp Parasitol; 2009 Apr; 121(4):362-9. PubMed ID: 19211022
[TBL] [Abstract][Full Text] [Related]
8. Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes.
Badiee A; Jaafari MR; Khamesipour A
Exp Parasitol; 2007 Feb; 115(2):127-34. PubMed ID: 16979165
[TBL] [Abstract][Full Text] [Related]
9. Immunoliposomes containing Soluble Leishmania Antigens (SLA) as a novel antigen delivery system in murine model of leishmaniasis.
Eskandari F; Talesh GA; Parooie M; Jaafari MR; Khamesipour A; Saberi Z; Abbasi A; Badiee A
Exp Parasitol; 2014 Nov; 146():78-86. PubMed ID: 25246326
[TBL] [Abstract][Full Text] [Related]
10. Intraperitoneal immunization with oligomannose-coated liposome-entrapped soluble leishmanial antigen induces antigen-specific T-helper type immune response in BALB/c mice through uptake by peritoneal macrophages.
Shimizu Y; Takagi H; Nakayama T; Yamakami K; Tadakuma T; Yokoyama N; Kojima N
Parasite Immunol; 2007 May; 29(5):229-39. PubMed ID: 17430546
[TBL] [Abstract][Full Text] [Related]
11. KSAC, a defined Leishmania antigen, plus adjuvant protects against the virulence of L. major transmitted by its natural vector Phlebotomus duboscqi.
Gomes R; Teixeira C; Oliveira F; Lawyer PG; Elnaiem DE; Meneses C; Goto Y; Bhatia A; Howard RF; Reed SG; Valenzuela JG; Kamhawi S
PLoS Negl Trop Dis; 2012; 6(4):e1610. PubMed ID: 22509423
[TBL] [Abstract][Full Text] [Related]
12. A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection.
Yamakami K; Akao S; Sato M; Nitta Y; Miyazaki J; Tadakuma T
Parasitol Int; 2001 Jul; 50(2):81-91. PubMed ID: 11438430
[TBL] [Abstract][Full Text] [Related]
13. Proteins of Leishmania (Viannia) shawi confer protection associated with Th1 immune response and memory generation.
Passero LF; Carvalho AK; Bordon ML; Bonfim-Melo A; Carvalho K; Kallás EG; Santos BB; Toyama MH; Paes-Leme A; Corbett CE; Laurenti MD
Parasit Vectors; 2012 Mar; 5():64. PubMed ID: 22463817
[TBL] [Abstract][Full Text] [Related]
14. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis.
Shargh VH; Jaafari MR; Khamesipour A; Jaafari I; Jalali SA; Abbasi A; Badiee A
Vaccine; 2012 Jun; 30(26):3957-64. PubMed ID: 22465747
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous leishmaniasis.
Bottrel RL; Dutra WO; Martins FA; Gontijo B; Carvalho E; Barral-Netto M; Barral A; Almeida RP; Mayrink W; Locksley R; Gollob KJ
Infect Immun; 2001 May; 69(5):3232-9. PubMed ID: 11292745
[TBL] [Abstract][Full Text] [Related]
16. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major.
Soussi N; Milon G; Colle JH; Mougneau E; Glaichenhaus N; Goossens PL
Infect Immun; 2000 Mar; 68(3):1498-506. PubMed ID: 10678966
[TBL] [Abstract][Full Text] [Related]
17. A lentiviral vaccine expressing KMP11-HASPB fusion protein increases immune response to Leishmania major in BALB/C.
Mortazavidehkordi N; Fallah A; Abdollahi A; Kia V; Khanahmad H; Najafabadi ZG; Hashemi N; Estiri B; Roudbari Z; Najafi A; Farjadfar A; Hejazi SH
Parasitol Res; 2018 Jul; 117(7):2265-2273. PubMed ID: 29845415
[TBL] [Abstract][Full Text] [Related]
18. The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers.
Iborra S; Abánades DR; Parody N; Carrión J; Risueño RM; Pineda MA; Bonay P; Alonso C; Soto M
Clin Exp Immunol; 2007 Nov; 150(2):375-85. PubMed ID: 17900304
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Leishmanization Using
Keshavarzian N; Noroozbeygi M; Haji Molla Hoseini M; Yeganeh F
Front Immunol; 2020; 11():1725. PubMed ID: 33193290
[No Abstract] [Full Text] [Related]
20. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK.
Tapia E; Pérez-Jiménez E; López-Fuertes L; Gonzalo R; Gherardi MM; Esteban M
Microbes Infect; 2003 Feb; 5(2):73-84. PubMed ID: 12650765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
